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thyroid, oesophagus, heart, lungs and kidneys was respectively 
15 Gy (9-23), 17 Gy (4-24), 8 Gy (2-13), 7 Gy (1-18) and 6 Gy (1-
12). Lung volume receiving 5 Gy (V5) was 50% (13-65%) and V20 
was 0 % (0-8%). For the entire cohort, two-year PFS and OS were 
75% and 93%, respectively. 
Conclusions: This large series confirms that HT CSI can achieve 
favourable clinical outcomes along with acceptable acute 
toxicities associated with low doses to organs at risk.  
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Purpose: The management of elderly patients with glioblastoma 
multiforme is evolving. Recent evidence suggests a treatment 
approach based on tumour molecular markers may improve 
outcomes in this population. Provincial guidelines were last 
updated in 2012. This report aimed to generate updated 
recommendations and provide the basis for provincial guideline 
development.  
Methods and Materials: The MEDLINE, EMBASE, PubMed and 
Cochrane databases were systematically searched for clinical 
trials published between January 2005 and January 2016 
evaluating treatment outcomes for elderly patients with 
glioblastoma.  
Results: Elderly is commonly defined as ≥ 65 years of age 
although definitions vary. Randomized controlled trials have 
compared different radiotherapy (RT) regimens, RT versus best 
supportive care alone, and different single-modality therapies 
(temozolomide [TMZ] versus RT) including subgroup analyses 
based on tumour MGMT promoter methylation status. Results 
from an international Phase III trial comparing combination 
RT/TMZ to RT alone are anticipated for release in the near 
future. 
Conclusions: 1) Elderly patients with Karnofsky Performance 
Status (KPS) ≥ 70 including those > 70 years of age should be 
offered RT in addition to best supportive care alone; 2) patients 
aged 65 years and older with KPS ≥ 70 may be considered for 
chemoradiotherapy. This guideline will be revisited following 
publication of the EORTC (26981-22981)/NCIC CTG (CE.3) trial; 
3) patients aged 65 years and older with KPS < 70, or with KPS > 
70% and wishing to avoid potential toxicities of combination 
therapy, may be offered single modality therapy. Patients should 
be tested for tumour MGMT promoter methylation. Those with 
methylated MGMT should be offered TMZ while those with non-
methylated MGMT should be offered RT. The alternate therapy 
may be offered at time of tumour progression; 4) The course of 
RT may be abbreviated to 40 Gy in 15 fractions in patients ≥ 60 
years of age, and to 25 Gy in 5 fractions in patients who are 
elderly (age ≥ 65 years and KPS 80 to 100%), frail (age ≥ 50 years 
and KPS of 50 to 70%) and elderly and frail (age ≥ 65 years and 
KPS of 50 to 70%). 
Based on these findings, a provincial working group will be 
formed to update current practice guidelines for the 
management of elderly patients with glioblastoma in Alberta. 
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Purpose:  Improvements in systemic therapy and diagnostic 
imaging are resulting in an increasing number of patients 
presenting with limited intracranial metastases. The optimal 
management of these patients is an area of active research. We 
aimed to establish a clinical practice guideline based on the best 
available evidence for the management of adult patients with 1-
3 brain metastases. 
Methods and Materials:  The MEDLINE, EMBASE, PubMed and 
Cochrane databases were systematically searched for clinical 
trials published between 2000 and 2015 evaluating treatment 
outcomes in patients ≥ 18 years of age with 1-3 brain metastases. 
Guideline recommendations were drafted and circulated to the 
Provincial CNS Tumour Team and a consensus survey was 
conducted. The recommendations were reviewed at the 2015 
Provincial CNS Tumour Team meeting and a guideline document 
was drafted and circulated to tumour team members and key 
stakeholders to achieve consensus. 
Results:  Prognostic scoring systems such as the recursive 
partitioning analysis (RPA) classification for brain metastases can 
aid in decision-making between more and less aggressive 
therapies. A favourable prognostic group includes patients with 
a Karnofsky Performance Score (KPS) ≥ 70, three or fewer 
cerebral metastases, and no progressive systemic disease. 
Patients with a favourable prognosis can be treated with multiple 
modalities, including: surgery, stereotactic radiosurgery (SRS), 
and/or whole brain radiation therapy (WBRT). Three randomized 
trials have compared outcomes in patients treated with surgery 
and WBRT compared to WBRT alone. Randomized trials have also 
investigated SRS with WBRT versus WBRT alone, and definitive 
therapy (SRS or Surgery) with versus without WBRT. Surgery and 
SRS have not been directly compared in a randomized trial. The 
methods for achieving group consensus on the drafted guidelines 
will be presented and discussed. 
Conclusions:  1) For patients with a single large symptomatic 
metastasis that is surgically accessible, total resection is 
recommended. SRS to the tumour bed and/or WBRT can be used 
to decrease the post-operative risk of recurrence; 2) SRS is an 
effective treatment for brain metastases less than 3 cm in 
diameter and especially in surgically inaccessible locations or 
patients who are not surgical candidates;  3) WBRT can be 
combined with surgery or SRS to increase local and regional 
disease control, but it may increase the likelihood of cognitive 
side effects without increasing overall survival; 4) 
Multidisciplinary discussions should be ongoing in regards to 
surveillance, imaging, and the use of options for initial and 
salvage treatment that balance cranial disease control and 
functional outcome. Patients are encouraged to participate in 
clinical trials. 
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Purpose:  Microsurgery and radiation treatment (RT) are 
therapeutic options for vestibular schwannomas (VS). Our 
purpose was to examine long-term outcomes in a geographically 
defined population of patients. 
Methods and Materials:  This is a population-based, 
retrospective review of 342 patients treated for VS between 
2002-2009, having a potential minimum follow up of five years. 
Patient management was routinely chosen after discussion in a 
provincial multidisciplinary conference. The primary endpoint 
was local control and the secondary endpoint was treatment-
related toxicity. Serviceable hearing (SH) was measured using 
the Gardner-Robertson scale and facial nerve dysfunction (FND) 
using the House-Brackmann (HB) grading. Progression free 
survival (PFS) was estimated using the Kaplan-Meier method. 
Serious adverse events (SAEs) were graded using the Common 
Terminology Criteria for Adverse Events (Version 4.03). 
